Syntekabio to Showcase Biologics Discovery Platform at PEGS Boston
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Syntekabio (226330.KQ), a global artificial intelligence (AI) drug discovery pioneer, today announced its participation at the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit, where the company will highlight its novel biologics platform.
- NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Syntekabio (226330.KQ), a global artificial intelligence (AI) drug discovery pioneer, today announced its participation at the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit, where the company will highlight its novel biologics platform.
- The event is being held May 13-17, 2024 at the Omni Hotel at the Seaport, Boston, MA.
- Jonathan Witztum, PhD, Chief Technology Officer at Syntekabio USA Inc., commented: “PEGS Boston is an excellent platform for us to present our in-silico biologics platform and our comprehensive set of AI-driven solutions for drug discovery.
- Don't miss the opportunity to meet with Syntekabio's team at Booth 40 to learn how the company’s services can find solutions to solve pipeline challenges, fast.